13. 多発性硬化症/視神経脊髄炎
[臨床試験数:3,050,薬物数:2,147(DrugBank:348),標的遺伝子数:244,標的パスウェイ数:228

Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
24 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03799718
(ClinicalTrials.gov)
March 13, 20197/1/2019Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MSA Phase 2 Open-label Multicenter Study to Evaluate the Safety and Efficacy of Repeated Administration of NurOwn® [Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (NTF), MSC-NTF] Cells in Participants With Progressive MSMultiple Sclerosis, Chronic ProgressiveBiological: NurOwn (MSC-NTF cells)Brainstorm-Cell TherapeuticsNULLActive, not recruiting18 Years65 YearsAll20Phase 2United States
2NCT03326505
(ClinicalTrials.gov)
September 25, 20179/5/2017Allogenic Mesenchymal Stem Cells And Physical Therapy for MS TreatmentThe Effect of Stem Cell Therapy and Comprehensive Physical Therapy in Motor and Non-Motor Symptoms in Patients With Multiple Sclerosis: A Comparative Study.Multiple SclerosisBiological: Umbilical cord derived Mesenchymal Stem Cells;Other: Supervised physical therapyUniversity of JordanNULLCompleted18 Years65 YearsAll60Phase 1;Phase 2Jordan
3NCT02239393
(ClinicalTrials.gov)
June 201510/9/2014Safety and Efficacy of Intravenous Autologous Mesenchymal Stem Cells for MS: a Phase 2 Proof of Concept StudyMEsenchymal Stem Cell Therapy for CAnadian MS PatientsMultiple SclerosisBiological: Mesenchymal Stem CellsOttawa Hospital Research InstituteNULLCompleted18 Years50 YearsAll31Phase 2Canada
4NCT02495766
(ClinicalTrials.gov)
May 11, 20153/6/2015Autologous Mesenchymal Stromal Cells for Multiple SclerosisTreatment of Autologous Mesenchymal Stem Cells Derived From Bone Marrow as a Potential Therapeutic Strategy for the Treatment of Multiple SclerosisRelapsing-Remitting Multiple Sclerosis;Secondary Progressive Multiple SclerosisDrug: XCEL-MC-ALPHA;Drug: PlaceboBanc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)Completed18 Years60 YearsAll8Phase 1;Phase 2Spain
5NCT02403947
(ClinicalTrials.gov)
February 20159/3/2015MEsenchymal StEm Cells for Multiple SclerosisTreatment of Multiple Sclerosis With Mesenchymal Stem Cells: Phase I/II StudyMultiple SclerosisDrug: Mesenchymal stem cells;Drug: Suspension mediaUniversity Hospital, ToulouseNULLTerminated18 Years50 YearsAll1Phase 1;Phase 2France
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT02587715
(ClinicalTrials.gov)
February 201526/10/2015A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMSAn Open-label, Non-randomized, Phase I/II Study of Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and Liberation Therapy (When Associated With Chronic Cerebrovascular Venous Insufficiency) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)Multiple Sclerosis, Relapsing-RemittingBiological: Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells;Other: Liberation therapyNovo Cellular Medicine Institute LLPNULLRecruiting18 Years60 YearsBoth69Phase 1;Phase 2Trinidad and Tobago
7NCT02418325
(ClinicalTrials.gov)
February 20158/4/2015A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMSAn Open-label, Non-randomized, Phase I/II Study of Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and Liberation Therapy (When Associated With Chronic Cerebrovascular Venous Insufficiency) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)Multiple Sclerosis, Relapsing-RemittingBiological: Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells;Other: Liberation therapyGenesis LimitedNULLTerminated18 Years60 YearsBoth69Phase 1;Phase 2Trinidad and Tobago
8NCT02166021
(ClinicalTrials.gov)
January 29, 201520/5/2014Clinical Efficacy of Autologous Mesenchymal Bone Marrow Stem Cells in Active & Progressive Multiple SclerosisPhase 2 Trial to Investigate the Clinical Efficacy & the Optimal Administration (Based on the Immunological, Clinical & Neuroradiological Effects) of Autologous Mesenchymal Bone Marrow Stem Cells in Active & Progressive Multiple SclerosisMultiple Sclerosis (MS)Biological: Mesenchymal stem cellsDimitrios KarussisNULLCompleted18 Years65 YearsAll48Phase 2Israel
9NCT02326935
(ClinicalTrials.gov)
November 201418/12/2014Multi-Center Study Safety of Adipose Derived Mesenchymal Stem Cells for the Treatment of Multiple SclerosisProposal for a Non-randomized, Patient Sponsored, Multi-center Study Studying the Impact and Safety of the Utilization of Culture Expanded Autologous, Adipose-derived Mesenchymal Stem Cells Deployed Via Intravenous Injection for the Treatment of Multiple SclerosisMultiple SclerosisBiological: Autologous adipose derived mesenchymal cellsAmerican CryoStem CorporationNULLTerminated18 Years65 YearsAll2Phase 1Cayman Islands
10EUCTR2012-000734-19-ES
(EUCTR)
10/04/201410/01/2014Bone marrow cell treatment as treatment of multiple sclerosisTreatment of autologous mesenchymal stem cells derived from bone marrow as a potential therapeutic strategy for the treatment of multiple sclerosis - EMMES Multiple Sclerosis
MedDRA version: 16.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: XCEL-MC-ALPHA
Product Code: XCEL-MC-ALPHA
INN or Proposed INN: Autologous adult mesenchymal stem cells from bone marrow expanded and cryopreserved
Other descriptive name: Mesenchymal Stem Cells
Banc de Sang i TeixitsNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Spain
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT02034188
(ClinicalTrials.gov)
January 20149/1/2014Feasibility Study of Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in Patients With Multiple SclerosisFeasibility Study of Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in Patients With Multiple SclerosisMultiple SclerosisBiological: Umbilical cord mesenchymal stem cellsTranslational BiosciencesNULLCompleted18 Years55 YearsAll20Phase 1;Phase 2Panama
12NCT02035514
(ClinicalTrials.gov)
December 201317/12/2013Phase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple SclerosisPhase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple SclerosisRelapsing Remitting Multiple Sclerosis (RRMS)Biological: Bone marrow autologous mesenchymal stem cells transplantationGermans Trias i Pujol HospitalMinisterio de Sanidad, Servicios Sociales e IgualdadCompleted18 Years50 YearsBoth9Phase 1;Phase 2Spain
13NCT01730547
(ClinicalTrials.gov)
February 20139/11/2012Mesenchymal Stem Cells for Multiple SclerosisPhase 1/2 Clinical Trial With Autologous Mesenchymal Stem Cells for the Therapy of Multiple SclerosisMultiple SclerosisBiological: Autologous mesenchymal stem cellsKarolinska InstitutetNULLRecruiting18 Years50 YearsBoth15Phase 1;Phase 2Sweden
14NCT01606215
(ClinicalTrials.gov)
January 201321/5/2012Stem Cells in Rapidly Evolving Active Multiple SclerosisStem Cells in Rapidly Evolving Active Multiple SclerosisMultiple SclerosisDrug: Mesenchymal stem cells;Drug: PlaceboImperial College LondonNULLCompleted18 Years50 YearsAll21Phase 1;Phase 2United Kingdom
15NCT02249676
(ClinicalTrials.gov)
January 201315/9/2014Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum DisordersAutologous Mesenchymal Stem Cells for the Treatment of Progressive and Refractory Neuromyelitis Optica Spectrum Disorders: an Open-label Phase 2a Proof-of-concept StudyDevic's Syndrome;Devic's Neuromyelitis Optica;Devic Syndrome;Devic's Disease;Devic DiseaseBiological: Autologous mesenchymal stem cellsTianjin Medical University General HospitalNULLCompleted18 Years80 YearsAll15Phase 2China
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16NCT03778333
(ClinicalTrials.gov)
December 1, 201214/1/2015Mesenchymal Stem Cells for Progressive Multiple Sclerosis_SwedenMesenchymal Stem Cells for Progressive Multiple Sclerosis_SwedenAutologous Mesenchymal Stem Cells;Multiple SclerosisBiological: Autologous mesenchymal stem cellsKarolinska InstitutetNULLCompleted18 Years65 YearsAll7Phase 1Sweden
17NCT01895439
(ClinicalTrials.gov)
October 201224/6/2013Safety and Efficacy Study of Autologus Bone Marrow Mesenchymal Stem Cells in Multiple SclerosisPhase II Study: Use of Autologus Mesenchymal Stem Cells in Multiple Sclerosis Patients Who do Not Respond to Conventional TreatmentMultiple SclerosisBiological: Autologous Mesenchymal Stem CellsUniversity of JordanNULLCompleted18 Years65 YearsAll13Phase 1;Phase 2Jordan
18NCT01854957
(ClinicalTrials.gov)
July 20128/5/2013MEsenchymal StEm Cells for Multiple SclerosisMEsenchymal StEm Cells for Multiple Sclerosis (MESEMS) Phase I-II Clinical Trial With Autologous Mesenchymal Stem Cells (MSCs) for the Therapy of Multiple SclerosisMultiple SclerosisBiological: Autologous Mesenchymal Stem CellsAntonio UccelliAzienda Ospedaliera Universitaria Integrata Verona;Ospedale San RaffaeleRecruiting18 Years50 YearsBoth20Phase 1;Phase 2Italy
19EUCTR2012-000518-13-DK
(EUCTR)
21/06/201221/06/2012Own mesenchymal stem cells for multiple sclerosis patientsImmunomodulating and neuroprotective properties of autologous multipotent mesenchymal stem cells in patients with multiple sclerosis - A randomised placebo-controlled double-blinded phase II study - COMSCIMS Multiple sclerosis
MedDRA version: 18.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Mesenchymal stem/stromal cells
Product Name: Mesenchymal stem cells (MSCs)
Prof. Per Soelberg SørensenNULLNot RecruitingFemale: yes
Male: yes
Phase 2Denmark
20NCT01377870
(ClinicalTrials.gov)
December 201119/6/2011Evaluation of Autologous Mesenchymal Stem Cell Transplantation (Effects and Side Effects) in Multiple SclerosisEffect and Side Effect of Mesenchymal Stem Cell in Multiple SclerosisMultiple SclerosisBiological: intravenous injection of mesenchymal stem cells;Biological: injection of cell free mediaRoyan InstituteNULLCompleted18 Years55 YearsAll22Phase 1;Phase 2Iran, Islamic Republic of
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
21NCT01228266
(ClinicalTrials.gov)
December 201025/10/2010Mesenchymal Stem Cell Transplantation in MSAutologous Mesenchymal Stem Cell Transplantation in Multiple Sclerosis: a Randomized, Double-blind, Crossover With Placebo Phase II StudyMultiple SclerosisBiological: autologous mesenchymal stem cellsAlbert SaizInstituto de Salud Carlos IIITerminated18 Years50 YearsBoth9Phase 2Spain
22NCT01364246
(ClinicalTrials.gov)
January 201031/5/2011Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis OpticaPhase I/II Study of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis OpticaProgressive Multiple Sclerosis;Neuromyelitis Optica.Biological: human umbilical cord mesenchymal stem cellsShenzhen Beike Bio-Technology Co., Ltd.The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School;The Affiliated Nanjing Brain Hospital of Nanjing University Medical School;Nanjing University Medical College Affiliated Wuxi Second Hospital;Xuzhou Medical College;The Second Hospital of Nanjing Medical UniversityRecruiting18 Years60 YearsBoth20Phase 1;Phase 2China
23NCT00781872
(ClinicalTrials.gov)
October 200628/10/2008Mesenchymal Stem Cells for the Treatment of MSExplorative Trial to Investigate the Migration Ability of Mesenchymal Bone Marrow Stem Cells (MSC) in the Central Nervous System (CNS) Following Their Intrathecal Administration in Severe Cases of Multiple Sclerosis (MS)Multiple SclerosisBiological: injection of autologous stem cellsHadassah Medical OrganizationNULLCompleted35 Years65 YearsAll20Phase 1;Phase 2NULL
24EUCTR2015-000137-78-AT
(EUCTR)
17/09/2015Mesenchymal stem cells therapy for patients with multiple sclerosisRandomised, double-blind, cross-over phase II study with intravenous autologous mesenchymal stem cells vs. placebo for multiple sclerosis patients in Austria (MESEMS Austria) multiple sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: Human autologous mesenchymal stem cells
INN or Proposed INN: MSC2015
Other descriptive name: UNDIFFERENTIATED AUTOLOGOUS MESENCHYMAL STEM CELLS
SALK - Gemeinnützige Salzburger Landeskliniken Betriebsges. m.b.H., Christian-Doppler-Klinik, UK für Neurologie der PMUNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Phase 2Austria